Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
30 June 2021Website:
http://www.cvrx.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:59:49 GMTDividend
Analysts recommendations
Institutional Ownership
CVRX Latest News
CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
CVRx announces the publication of positive study data for its Barostim therapy.
Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is CVRx?
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
What sector is CVRx in?
CVRx is in the Healthcare sector
What industry is CVRx in?
CVRx is in the Medical Devices industry
What country is CVRx from?
CVRx is headquartered in United States
When did CVRx go public?
CVRx initial public offering (IPO) was on 30 June 2021
What is CVRx website?
https://www.cvrx.com
Is CVRx in the S&P 500?
No, CVRx is not included in the S&P 500 index
Is CVRx in the NASDAQ 100?
No, CVRx is not included in the NASDAQ 100 index
Is CVRx in the Dow Jones?
No, CVRx is not included in the Dow Jones index
When was CVRx the previous earnings report?
No data
When does CVRx earnings report?
Next earnings report date is not announced yet